Pokrupa 1986.

Methods	Randomisation by sealed numbered opaque envelope Double‐blind, placebo‐controlled, single‐centre trial Intention‐to‐treat No loss to FU
Participants	Canada 11 male, 12 female Mean age 63 years 100% CT pre‐entry Enrolment within 48 hours of ictus
Interventions	Rx: PGI2 ("Cycloprostin", Upjohn Co., USA) 5 daily 8 hour consecutive infusions weaned up from 2 to 10 ng/kg/min and tapered over last hour Pl: sterile diluent buffer (NaCl 0.147 w/v, glycine 0.188 w/v, NaOH, pH 10.5 +/‐ 0.3) Duration: 5 days
Outcomes	Death at 5 days, and 1, 2 and 4 weeks Neurological impairment rating at 5 days, and 1, 2 and 4 weeks CT and PET at 5 to 9 days
Notes	Ex: coma, complicating neurological conditions, heparin, malignant hypertension, uncontrolled diabetes mellitus, heart attack within 2 months, recent surgery FU: 5 days, and 1, 2, and 4 weeks Original data available
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate

CI: cerebral infarction 
 Ex: exclusion 
 FU: follow up 
 PICH: primary intracerebral haemorrhage 
 iv: intravenous 
 PGI2: prostacyclin 
 Pl: placebo 
 Rx: treatment